

# PREDICT: NTM observational study (NTM-OB-17 (PREDICT))

## Summary

This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

Researchers will test the effectiveness of NTM diagnosis standards by measuring how many people with a positive culture for NTM are diagnosed with NTM. Researchers will also track clinical results and types of NTM that occur more frequently in particular regions of the country.

This study is for people with cystic fibrosis who are enrolled in the CF Foundation Patient Registry and have a positive culture for NTM within the past two years that has never been treated. This study is not for people who have had an organ or blood transplant or who are being treated for the type of NTM infection relevant to this study.

## Specimen Information

**Status: Specimens are Not yet available, anticipated November, 2022**

Blood and Urine are collected at enrollment, annually, and at the time of NTM disease diagnosis

Visit #	Time From Baseline	Specimens Collected
1	+0 Days	EDTA plasma, Serum, Urine
2	+1 Years	EDTA plasma, Serum

### Study Design

Study Type?	Observational
Randomized Study?	No
Placebo Controlled?	No
Length of Participation	5 Years
Number of Study Visits?	20

### Additional Information

Phase?	Not Applicable
--------	----------------

**Study Sponsor?** Nick, Jerry

**Study Drugs?** N/A



**Age** 6 Years and Older

**Mutation(s)** No Mutation Requirement

**FEV1% Predicated** No FEV1 Limit

**PA Status** Not Applicable

**Other**

## Study Results

STUDY RESULTS NOT YET AVAILABLE

For more information about the results of this study and where it was conducted, visit [ClinicalTrials.gov](https://ClinicalTrials.gov).